Vitek 2 gn identification cards

Oxi/Ferm Pluri Test^® (Liofilchem, Italy) was used. Next, the automatic characterization was carried out with the VITEK^® 2 equipment and with the VITEK^®2 GN identification cards (bioMérieux, Marcy-l’Étoile, France). The motility of the bacterium was tested in Motility Test Agar, (Liofilchem, Italy). Antimicrobial sensitivity was determined using E-test in Müller Hinton agar (Pronadisa^®, Madrid, Spain) using the following antibiotics: piperacillin and piperacillin with tazobactam, cefepime (bioMérieux, Marcy-l’Étoile, France); ceftazidime, imipenem, imipenem with EDTA, amikacin, gentamicin, and ciprofloxacin (Liofilchem, Italy).

Oxi/Ferm Pluri Test^® (Liofilchem, Italy) was used. The automatic characterization was then carried out using the VITEK^®-2 GN identification cards (bioMérieux, Marcy-l’Étoile, France). The motility of the bacterium was tested in Motility Test Agar (Liofilchem, Italy). Antimicrobial sensitivity was determined using E-test in Müller Hinton agar (Pronadisa^® Madrid, Spain) using different antibiotics for each strain. For SAICEU11^T strain we used cefepime and sulfamethoxazole and trimethoprim (bioMérieux, Marcy-l’Étoile, France); amoxicillin, amoxicillin-clavulanic acid, cefotaxime, cefpirome ciprofloxacin and nalidixic acid (Liofilchem, Italy). For SAICEU22^T strain we used piperacillin and piperacillin with tazobactam, cefepime (bioMérieux, Marcy-l’Étoile, France); ceftazidime, imipenem, imipenem with EDTA, amikacin, gentamicin, and ciprofloxacin (Liofilchem, Italy).
Mercury MBC was performed in Müller Hinton agar (Pronadisa^®, Madrid, Spain), supplemented with different concentrations of HgCl₂: 400, 350, 200, 175, 150, 100, 87.5, 75, 50, 43.75, and 25 μg mL⁻¹. MBC was determined as the lowest concentration of HgCl₂ capable of inhibiting > 99.9% of bacterial growth.